argenx SE American Depositary Receipt (ARGX)
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
argenx: The Sjögren's Selloff Looks Overdone
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. VYVGART franchise remains robust, driving strong cash generation and funding pipeline advancements, despite setbacks in expanding indications. At ~8x annualized sales, ARGX trades at a discount to peers like Vertex, supporting a reiterated 'Buy' rating based on growth prospects.
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune condition characterized by immune-mediated destruction of the glands that produce tears and saliva, causing symptoms including dry eyes and mouth.
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
Argenx says efgartigimod met main goal in myositis trial
Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint in a late-stage study treating adults with autoimmune myositis, showing significant improvement in disease activity.
What Makes Argenx (ARGX) a New Buy Stock
Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.
argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
I upgrade argenx to BUY with a $1,050 price target, citing sustained VYVGART growth, label expansion, and a strong balance sheet. VYVGART's commercial momentum is robust, with expanded indications, at-home administration, and a growing prescriber base supporting long-term growth. Pipeline optionality, notably empasiprubart and autoimmune myositis, provides meaningful upside not fully reflected in ARGX's current valuation.
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease.
argenx: Vyvgart Is Taking Off (Rating Upgrade)
argenx delivered a Q2 marked by surging profitability, robust cash generation, and operational leverage from its autoimmune franchise. ARGX's efgartigimod franchise, especially in gMG, underpins a $50B+ enterprise value, with pipeline catalysts like empasiprubart in MMN on the horizon. With $3.6B in cash, minimal debt, and self-funded R&D, ARGX is well-positioned for continued innovation and pipeline expansion.
argenex Q2 Earnings Call Highlights
argenex NASDAQ: ARGX reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, as well as early momentum from a newly expanded label in generalized myasthenia gravis.
